DIRS.INFO The most relevant business & tech news

☆ AstraZeneca shares fall on report of potential China probe fallout
▼ + stars: | 2024-11-05 | by ( ) www.cnbc.com time to read: +2 min

The Astrazeneca logo is pictured at the World Artificial Intelligence Conference 2021 in Shanghai, China, July 7, 2021. "As a matter of policy, we do not comment on speculative media reports including those related to ongoing investigations in China," AstraZeneca said. "If requested, we will fully cooperate with the Chinese authorities," the company added and said that its operations and delivery of medicines were ongoing in China. AstraZeneca is one of the biggest multinational drugmakers in China, which accounts for 13% of its overall revenue. In 2022, Chinese authorities had summoned AstraZeneca officials over an investigation of suspected medical insurance fraud by its employees, and had ordered that the drugmaker tighten its marketing activities.

Persons: Leon Wang, Wang, AstraZeneca Organizations: Astrazeneca, Artificial Intelligence, AstraZeneca, country's pharma Locations: Shanghai, China, Swedish

☆ Pfizer tops earnings estimates, hikes full-year guidance as Covid products help sales
▼ + stars: | 2024-10-29 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Pfizer on Tuesday reported third-quarter revenue and adjusted profit that blew past expectations as the company's Covid vaccine and antiviral pill Paxlovid helped boost sales. Pfizer now expects revenue in a range of $61 billion to $64 billion, up from a previous revenue forecast of between $59.5 billion to $62.5 billion. That includes roughly $5 billion in expected revenue from its Covid vaccine and $5.5 billion from Paxlovid. Pfizer reported revenue of $17.7 billion for the third quarter, up 31% from the same period a year ago. Notably during the quarter, Pfizer withdrew from world markets a critical sickle cell drug it had acquired in a $5.4 billion deal for Global Blood Therapeutics.

Persons: Jeff Smith, Smith, Paxlovid, StreetAccount, Covid Organizations: Pfizer, LSEG, Global Blood Therapeutics Locations: U.S

☆ Lilly sues online vendors, medical spa over copycat weight-loss drugs
▼ + stars: | 2024-10-21 | by ( ) www.cnbc.com time to read: +3 min

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound, including in the form of dissolvable tablets. Pivotal Peptides says it offers research grade tirzepatide, while MangoRx sells a compounded version, both online. Lilly has accused Pivotal Peptides of selling products claiming to contain tirzepatide directly to patients without any prescription from a medical professional, despite advertising the drugs for research purposes. Lilly said it sent a cease and desist letter to Pivotal Peptides before filing the lawsuit. Eli Lilly is seeking court orders barring the vendors from selling their drugs claiming to contain tirzepatide and unspecified monetary damages.

Persons: Eli Lilly’s, Eli Lilly, tirzepatide, Lilly, MangoRx, drugmaker, Genesis Organizations: Lifestyle Medicine of, U.S . Food, Drug Administration, Genesis, FDA, B12 Locations: New York City, Lifestyle Medicine of Nevada, U.S, Indiana , Texas, Washington, Indianapolis

☆ Cheap stocks to buy in the fourth quarter, according to HSBC
▼ + stars: | 2024-10-05 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

It's officially a new trading month, and HSBC recommends investors broaden their exposure in the fourth quarter by seeking out stocks with more reasonable valuations. "These 'big' companies represent the lion's share of equity index returns year to date." HSBC has a buy rating on the stock. In all, 16 of the 29 analysts covering GM have a strong buy or buy rating, and its average price target of $54.35 implies nearly 19% upside from Friday's close, per LSEG. The remaining 11 have a buy or strong buy rating.

Persons: It's, Nicole Inui, General Motors, Goldman Sachs, Goldman Organizations: HSBC, Dow, Industrial, Nasdaq, Federal Reserve, General, GM, Pharmaceutical, Pfizer, Delta Air Lines Locations: Americas, U.S

☆ Novo Nordisk CEO to testify at Senate hearing over high weight loss drug prices
▼ + stars: | 2024-09-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Lars Fruergaard Jørgensen, CEO of Novo Nordisk, speaks during an interview in New York on Aug. 10, 2022. Novo Nordisk 's top executive is slated to face a Senate grilling on Tuesday over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic, as demand for both injections soars in the U.S.Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate Health, Education, Labor and Pensions Committee hearing at 10 a.m. It comes roughly five months after Sen. Bernie Sanders, the Vermont independent who chairs the Senate panel, opened an investigation into the Danish drugmaker's pricing practices. Sanders contends that Novo Nordisk charges Americans substantially higher prices for its blockbuster drugs than it does for patients in other countries. Before insurance, Ozempic costs nearly $969 per month and Wegovy costs almost $1,350 per month in the U.S.

Persons: Lars Fruergaard Jørgensen, Sen, Bernie Sanders, Sanders Organizations: Novo Nordisk, Health, Education, Labor, Washington , D.C, Nordisk Locations: New York, U.S, Washington ,, Vermont, Danish, Germany

☆ Stocks making the biggest moves midday: FedEx, Nike, Constellation Energy and more
▼ + stars: | 2024-09-20 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Constellation Energy – Shares surged more than 17% after the company announced plans to restart the Three Mile Island nuclear plant and sell that power to Microsoft to satisfy the energy needs of its data centers. ASML – The semiconductor stock slid 3.4% in the wake of a Morgan Stanley downgrade to equal weight from overweight. Morgan Stanley said the risk-to-reward ratio has been "balancing." Centessa Pharmaceuticals – The biotech stock rose more than 4% after Morgan Stanley upgraded it to overweight from equal weight. Valero Energy – The energy stock declined nearly 3% after a Piper Sandler downgrade to neutral from an overweight rating, citing "less room for outperformance."

Persons: Raj Subramaniam, Elliott Hill, John Danahoe, Eli Lilly's orforglipron, Eli Lilly, Vistra, it's, Donald Trump, Lennar, ASML, Morgan Stanley, Piper Sandler, Buddy Chester, Alex Harring, Brian Evans, Samantha Subin, Yun Li, Lisa Kailai Han, Jesse Pound, Michelle Fox Organizations: FedEx, Nike, Constellation Energy, Microsoft, Novo Nordisk –, Deutsche Bank, Corbus Pharmaceuticals, Novo Nordisk's, Viking Therapeutics, Vision, Trump Media & Technology, Pharmaceuticals, Valero Energy Locations: Novo, Texas

WASHINGTON — Sen. Bernie Sanders, I-Vt., renewed his criticism of drugmaker Novo Nordisk on Tuesday, claiming that the CEOs of major generic pharmaceutical companies have told him that they can produce and sell its blockbuster diabetes drug Ozempic for less than $100 a month. During Tuesday's roundtable, Sanders said his recent conversations with generic drugmakers revealed that Novo Nordisk's pricing is "nothing less than excess corporate greed." “They have studied the math, and they tell me that they can sell a generic version of Ozempic, the exact same drug that Novo Nordisk is manufacturing, to Americans for less than $100 a month," Sanders said. Sanders’ office declined to say which generic drug companies told him that they could sell Ozempic at a fraction of what Novo Nordisk charges. Novo Nordisk did not immediately respond to a request for comment.

Persons: WASHINGTON — Sen, Bernie Sanders, Sanders, Lars Fruergaard Jorgensen's, Jorgensen, Wegovy, Dale Folwell, Eli Lilly's Organizations: drugmaker Novo Nordisk, Capitol, Novo Nordisk, Health, Education, Labor, Pensions, Wegovy, Nordisk, Yale Locations: U.S, Novo, Denmark, Germany, United Kingdom, North Carolina

☆ Eli Lilly's earnings rally is not done yet — plus, why TJX has stayed resilient in the volatility
▼ + stars: | 2024-08-09 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. It's a big one for retail with earnings from Home Depot and Walmart and, more broadly, the Commerce Department's July retail sales report. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Eli Lilly, Cowen, TJ Maxx, we'll, Jim Cramer's, Jim Organizations: CNBC, Taiwan Semiconductor Manufacturing Company, Apple, Nvidia, Management, Home Depot, Walmart, Commerce, TJX, Reserve, Jim Cramer's Charitable Locations: Marshall's

☆ These stocks have fallen too much, too fast and could be due for a rebound after broad market sell-off
▼ + stars: | 2024-08-02 | by ( Hakyung Kim | ) www.cnbc.com time to read: +3 min

This week's market sell-off has pushed several stocks into oversold territory — potentially setting these names for a rebound in the future. Troubled cybersecurity stock CrowdStrike is the most oversold stock on the list with an RSI of just 13.6. Some of this week's most overbought companies include defense giant Lockheed Martin , tobacco company Philip Morris International and FirstEnergy . Of the names on the list, Lockheed Martin has the highest 14-day RSI reading of 93.7. LMT YTD mountain Lockheed Martin in 2024

Persons: Goldman Sachs, LULU, Lockheed Martin, Philip Morris Organizations: Nasdaq, Dow Jones, CNBC, Moderna, U.S, Street, Lockheed, Philip Morris International, Bank of America Locations: LSEG, Thursday's

☆ Stocks making the biggest moves midday: Shake Shack, C.H. Robinson, Mobileye Global and more
▼ + stars: | 2024-08-01 | by ( Sean Conlon | ) www.cnbc.com time to read: +5 min

However, it topped second-quarter revenue estimates and posted a narrower-than-expected loss for the quarter. Teladoc — The telehealth stock moved more than 4% lower after the company posted weaker-than-expected second-quarter revenue. Air Products and Chemicals — The industrial gases company's stock surged more than 10% after beating Wall Street's earnings expectations. MGM Resorts — The stock declined nearly 14% despite the casino operator surpassing second-quarter earnings expectations. Crocs — The stock shares fell about 2% even though the company surpassed second-quarter earnings and revenue expectations.

Persons: Shack, C.H, Robinson, Teladoc, LSEG, Royce —, Royce, Wall, Meta, Carvana, Crocs, Akash Palkhiwala, —, Samantha Subin, Yun Li, Michelle Fox Organizations: LSEG, Moderna, Royce, Air Products, Chemicals, Meta, MGM Resorts, MGM, Arm, Holdings, Qualcomm Locations: LSEG ., U.S

☆ Jim Cramer: Merck is a buy after the drugmaker's post-earnings dip — here's why
▼ + stars: | 2024-07-30 | by ( Matthew J. Belvedere | ) www.cnbc.com time to read: +1 min

Merck : The drugmaker reported a better-than-expected quarter. It raised its full-year sales outlook but was still a little short of estimates. Jim Cramer said Tuesday he would take advantage of the dip and buy Merck ahead of the benefit from this drug. Pfizer : Better-than-expected sales and adjusted earnings, as well as a full-year outlook raise, were not enough to keep the stock higher. PayPal : The digital payments company reported a better-than-expected quarter.

Persons: Jim Cramer's, Jim Cramer, Cramer, Alex Chriss, Anthony Noto Organizations: CNBC, Club, Merck, FDA, Pfizer, PayPal, Aerospace

☆ Stocks making the biggest moves midday: JetBlue, Sprouts Farmers Market, Varonis Systems and more
▼ + stars: | 2024-07-30 | by ( Sean Conlon | ) www.cnbc.com time to read: +6 min

Check out the companies making headlines in midday trading: JetBlue — The airline soared almost 20% after reporting second-quarter earnings that beat analysts' expectations . The Phoenix-based grocery chain also raised its full-year earnings guidance, forecasting revenue rising between 9% and 10%, compared to analysts' 8.2% consensus growth estimate. Revenue of $695 million was higher than the $686 million analysts has estimated. Lattice Semiconductor — Shares pulled back 8.5% after second-quarter earnings and current-quarter revenue guidance came in below expectations. Howmet Aerospace — The aerospace manufacturer rallied 14% after second-quarter earnings and revenue beat Wall Street estimates.

Persons: Varonis, Woodward, FactSet, LSEG, Howmet, Corning, Gamble —, Stanley Black, Decker, —, Alex Harring, Samantha Subin, Lisa Kailai Han, Hakyung Kim Organizations: JetBlue —, New, Revenue, Systems, FactSet, Inc, —, Technology, Semiconductor, Bank of America, CNBC, Delta Air Lines, Microsoft, Merck, Howmet Aerospace, Wall, PayPal, LSEG, Procter, Technologies Locations: New York City, LSEG, New Jersey, Cincinnati, Connecticut

☆ Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
▼ + stars: | 2024-07-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +5 min

George Frey | ReutersAn older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer's disease by protecting patients' brains, according to data from a mid-stage trial released on Tuesday. Novo Nordisk sells liraglutide as a diabetes and obesity drug under the brand names Victoza and Saxenda, respectively. Alzheimer's disease often causes the brain to shrink as the illness progresses because crucial nerve cells break down and stop working properly. By 2050, the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S. The ongoing EVOKE is examining semaglutide, the active ingredient in Wegovy and Ozempic, in nearly 2,000 Alzheimer's patients.

Persons: George Frey, Eli Lilly, liraglutide, Brian B, Bettencourt, Heather Snyder, Leqembi, Snyder, Dr, Paul Edison, Edison, Bobby Pugh, Bessie Pugh, Karen Pulfer Focht Organizations: Novo Nordisk Pharmaceutical, Reuters, Novo Nordisk, Imperial College London, Alzheimer's Association International Conference, Toronto Star, Getty, Alzheimer's Association, U.S, CNBC, Alzheimer's, Novo Nordisk's, Ave Locations: Provo , Utah, Danish, Philadelphia, Biogen, Novo, Bartlett , Tennessee, U.S

☆ Why Jim Cramer expects 3M to remain a 'big winner' — plus, his thoughts on 4 more stocks
▼ + stars: | 2024-07-29 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +2 min

Jim Cramer's daily rapid fire looks at stocks in the news outside the CNBC Investing Club portfolio. 3M: Shares were slightly lower Monday, giving back some of their 23% surge Friday on the back of a better-than-expected quarter and raised outlook. New CEO Bill Brown, who took over at the industrial firm May 1, had success at L3Harris Technologies and "will be a big winner here," as well, Jim Cramer said. McDonald's : Shares rose 4% despite the fast-food giant reporting weaker-than-expected earnings and revenue along with same-store sales declines. That's the stuff that's moving up" while buzzier chip stocks tied to artificial intelligence, such as Arm Holdings , are struggling, Cramer explained.

Persons: Jim Cramer's, Bill Brown, Jim Cramer, Cramer Organizations: CNBC, Club, L3Harris Technologies, Bristol Myers Squibb, Semiconductor, Wall, Texas Instruments, Arm Holdings, Colgate, Palmolive

☆ Bristol Myers surges 10%, its biggest increase since 2008, after boosting profit forecast
▼ + stars: | 2024-07-26 | by ( Kelly Cloonan | ) www.businessinsider.com time to read: +3 min

Bristol Myers boosted its adjusted earnings for the year to between 60 and 90 cents a share, up 20 cents from its last forecast. AdvertisementOf Bristol Myers' existing drugs, Eliquis saw a 7% increase in sales year-over-year. Cancer drug Opdivo and blood cancer treatment Revlimid also saw promising results and beat quarterly sales estimates. The company reiterated its plan to cut $1.5 billion in costs by 2025, which was announced at its last quarterly earnings call. Bristol Myers is only the latest of a host of other drugmakers to raise their earnings guidance this week.

Persons: Myers, —, Bristol Myers, Christopher Boerner, Eliquis, Revlimid, David Elkins, Boerner, AbbVie Organizations: Bristol, Myers Squibb, Service, Cancer, FDA, AstraZeneca, Roche, Sanofi Locations: Bristol

☆ Pfizer struggles to claw back faith with Wall Street and its employees as it recovers from the Covid decline
▼ + stars: | 2024-06-28 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +19 min

But other current employees are dissatisfied with where the strategy shift has left them. In January 2023, Pfizer forecast a steep drop in annual revenue, to between $67 billion and $71 billion. Pfizer's 2023 revenue ultimately came in at $58.5 billion, including $11.22 billion from its Covid vaccine and $1.28 billion from Paxlovid. Faith in executive leadership also plunged among some workers, according to most of the current and former employees who spoke with CNBC. Some current workers said that hasn't appeared to change after the town hall on May 2.

Persons: Albert Bourla, Wall, they're, Bourla, I'm, drugmaker Seagen, Irfan Khan, hasn't, Pfizer, renegotiating, John Thys, Payal Sahni Becher, Becher, Kena, Mike McDermott, Bourla's Organizations: Corbis, Getty, Pfizer, Wall, CNBC, Los Angeles Times, Moderna, Centers for Disease Control, U.S ., GSK, Bristol Myers Squibb, Pfizer wasn't, . Biotech, Companies, Biotech, BioNtech, Reuters, Human, View Press, Global, APEC, Summit, Tech, Google Locations: U.S, Covid, Eagle Rock , California, Durham , North Carolina, Puurs, Belgium, New York City, Peapack , New Jersey, Kena

☆ FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
▼ + stars: | 2024-06-07 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

But the virus can also cause severe illness in adults 50 and up — or even younger — with underlying chronic conditions such as asthma, diabetes and congestive heart failure. GSK's shot won't reach that new patient population just yet. Safety data in adults ages 50 to 59 was also consistent with data in adults 60 and above, according to GSK. Regulatory agencies in Europe, Japan and other areas are currently reviewing GSK's application to expand Arexvy's approval to high-risk adults ages 50 to 59. GSK's shot is approved in nearly 50 countries, a spokesperson for the company told CNBC.

Persons: Phil Dormitzer, Dormitzer, Luke Miels, Arexvy, GSK's Organizations: Drug Administration, GSK, FDA, Centers for Disease Control, CNBC, CDC, Pfizer, Moderna, U.S Locations: British, Europe, Japan

☆ Move over 'Magnificent 7,' the 'Fantastic 5' may offer higher earnings and return potential
▼ + stars: | 2024-06-06 | by ( Pia Singh | ) www.cnbc.com time to read: +6 min

Looking for a less risky way to find growth stocks amid all the artificial intelligence hype? Looking ahead, Thornburg expects the Fantastic Five's outperformance to continue, with the forward price-to-earnings ratio of the European group falling below the seven U.S. stocks starting in 2026 and running through 2028. The money manager also projected that the European group will increase earnings 18% a year over the next three years versus 14% for the "Mag 7." ASML, the biggest producer of the equipment used to manufacture semiconductors, makes "leading-edge" lithography equipment needed to produce AI chips, Anderson said. He manages the Thornburg International Growth Fund , a concentrated portfolio of high-quality companies based outside the U.S., which has gained 8.8% year-to-date.

Persons: Nicholas Anderson, Anderson, Thornburg, It's, it's, FactSet, ASML Organizations: Thornburg Investment Management, Novo Nordisk, ASML, LVMH, AstraZeneca, SAP, Nvidia, Big Tech, Microsoft, Apple, GLP, Nordisk, Taiwan Semiconductor, Bloomberg, Growth Fund Locations: U.S, Novo, Europe, Belgium

☆ Alphabet's new CFO was in the middle of the GLP-1 boom. Now she's onto generative AI
▼ + stars: | 2024-06-06 | by ( Jennifer Elias | ) www.cnbc.com time to read: +10 min

Alphabet announced on Wednesday that Eli Lilly Chief Financial Officer Anat Ashkenazi will be its new CFO after an almost year-long search. Shares of Eli Lilly have soared 90% in the past year and are trading at a record. When she joined Eli Lilly in 2001, she came in through the company's new venture capital division, which was co-founded by her then-spouse Ron Laufer. Fastest growth in decadesFounded in 1876, Eli Lilly has long been one of the major U.S. pharmaceutical companies. But the last couple years have marked a period of historic growth for Eli Lilly due to the exploding popularity of GLP-1s.

Persons: Anat Ashkenazi, Eli Lilly Eli Lilly Alphabet's, Ruth Porat, Eli Lilly, Ashkenazi, it's, Eli Lilly's, David Ricks, Morgan Stanley, Sundar Pichai, Hollie Adams, Ron Laufer, John Smiley, Eli, It's, Trump, Eli Lilly's Covid, we're, Askhenazi, OpenAI's, Larry Page, Sergey Brin, CNBC's Eric Rosenbaum, Toby Lyles Organizations: San, San Francisco Bay Area, Google, Economic, Bloomberg, Getty, CNBC, Tel Aviv University, Hebrew University, U.S . Food, Drug, U.S . Department of Justice, FDA, Reuters, Employees, NBC Locations: U.S, Indiana, San Francisco Bay, Davos, Switzerland, Israel, biopharma, North Carolina, Germany, New Jersey

☆ Here's why Cramer says Ford stock must be 'bought aggressively' on the dip
▼ + stars: | 2024-06-05 | by ( Morgan Chittum | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Ford, Jim, Eli Lilly, Anat Ashkenazi, Ashkenazi, shakeup, isn't, Jim Cramer's Organizations: CNBC, Federal Reserve, Nasdaq, Nvidia, Apple, Microsoft

Here's a rapid-fire update on all 33 stocks in Jim Cramer's Charitable Trust, the portfolio we use for the CNBC Investing Club. Below $200 a share is the level we'd get interested in buying more Salesforce stock, Jim said. The industrial name will continue to be a beneficiary of the AI trade due to Eaton's booming data center business. Alphabet : If this mega-cap name experiences a move lower, investors should scoop up shares, Jim said. Nvidia : There's not much more to say about Nvidia in light of another blowout earnings report and the strong guidance accompanying it.

Persons: Jim Cramer's, Jim, Apple's, Goldman Sachs, Salesforce, We've, Danaher, he'd, Walt Disney, We're, Estee Lauder, Eaton, Ford, Motors, Mary Dillon's, It's, Linde, Eli Lilly, Mark Zuckerberg's, Morgan Stanley, we're, Stanley Black, we've, Wynn, Jim Cramer, Michael M Organizations: Jim Cramer's Charitable Trust, CNBC, Club, Apple, Abbott Laboratories, Abbott Labs, Amazon Web Services, Broadcom, Dell, Samsung, Costco Wholesale, Coterra Energy, DuPont De Nemours, DuPont, The, Eaton, Ford, GE Healthcare, Honeywell, Jim, Linde, Microsoft, Nvidia, Palo Alto Networks, Palo Alto, Change, Procter & Gamble, Constellation Brands, Constellation, Modelo, Corona, Federal Reserve, TJX, Marshalls, Wynn Resorts, Jim Cramer's Charitable, Traders, New York Stock Exchange, Santiago, Getty Locations: China, Dover, Eaton, U.S, Maxx, HomeGoods, Wells Fargo, Macau, New York City

☆ Amgen scraps experimental weight loss pill, moves forward with injection
▼ + stars: | 2024-05-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Amgen on Thursday said it will stop developing its experimental weight loss pill and instead move forward with its injectable drug and other products in development for obesity. Amgen is developing an injectable obesity treatment called MariTide, which is an ongoing mid-stage trial in obese or overweight adults without diabetes. The drugmaker's oral drug, called AMG-786, is the second weight loss pill to be discontinued over the last year. Investors are laser-focused on Amgen's pipeline of experimental weight loss treatments. Amgen's injectable treatment also appears to help patients keep weight off after they stop taking it based on some clinical trial data.

Persons: Amgen, Eli Lilly, Jay Bradner, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, Zepbound Organizations: Novo Nordisk, Pfizer, Novo Nordisk's Locations: Amgen, Thousand Oaks , California, MariTide, Novo

☆ Stocks making the biggest moves midday: Super Micro Computer, Starbucks, Pfizer and more
▼ + stars: | 2024-05-01 | by ( Pia Singh | ) www.cnbc.com time to read: +4 min

Super Micro Computer — The server vendor dropped 15% after missing revenue expectations for its fiscal third quarter. However, Super Micro beat analysts' expectations for its adjusted earnings and hiked its revenue guidance for its fiscal 2024 year. Starbucks posted adjusted earnings of 68 cents per share on revenue of $8.56 billion. Pfizer now expects adjusted earnings of $2.15 to $2.35 per share for the full year, higher than its previous forecast of $2.05 to $2.25 per share. Yum Brands — The fast-food giant lost nearly 4% after it reported quarterly adjusted earnings and revenue that missed analysts' expectations.

Persons: Joseph Otting, —, Cowen, Skyworks, SiriusXM, Goldman Sachs, Powell, Estée Lauder —, Estée Lauder, Kraft Heinz, Pinterest's, Alex Harring, Yun Li, Lisa Kailai Han, Hakyung Kim, Michelle Fox Organizations: New York Community Bank, Super Micro, Starbucks, Pfizer, Apple, Amazon Web Services, CVS, Powell Industries, Wall, LSEG, Brands, KFC, Pizza, Taco, JPMorgan Locations: Houston, Taco Bell's

☆ Jim Cramer shares his thoughts on Caterpillar, Dow, Chipotle, Merck and ServiceNow
▼ + stars: | 2024-04-25 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +2 min

Shares fell more than 7%. Dow Inc : Shares fell more than 1.5% despite the chemicals maker reporting better-than-expected results. I'd buy the stock," Cramer said. Chipotle : The burrito chain reported better-than-expected sales and earnings, with same-store sales growth of 7% easily surpassing Wall Street estimates. ServiceNow : Shares fell more than 6% despite the maker of workflow software's quarterly results beating on the top-and-bottom lines.

Persons: Jim Cramer's, Jim Cramer, I'd, Cramer, Bill McDermott Organizations: CNBC, Club, Caterpillar, Dow Inc, Wall, Merck Locations: Dover

☆ Viking Therapeutics stock jumps more than 25% on promising weight loss pill data
▼ + stars: | 2024-03-26 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Viking Therapeutics shares jumped more than 25% on Tuesday after the company said its experimental weight loss pill showed positive results in a small study and will enter the next stage of development later this year. The study results add to the excitement around the drugmaker's prospects in the budding weight loss drug market. Based on Tuesday's results, Viking plans to start a phase two trial of its weight loss pill later this year. Weight loss for those patients ranged up to 3.6% higher than those who received a placebo. Viking CEO Brian Lian said during a conference call on Tuesday that it's unclear "how durable" the weight loss is.

Persons: Eli Lilly, Viking, Brian Lian Organizations: Viking Therapeutics, Novo Nordisk, Viking

Search resuls for: "drugmaker's"

25 mentions found